12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Subcutaneous Orencia abatacept regulatory update

Bristol-Myers said the European Commission approved subcutaneous Orencia abatacept to treat moderate to severe rheumatoid arthritis (RA) in combination with methotrexate in adults. IV...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >